Scientific journal
European Student Scientific Journal
ISSN 2310-3094
ISSN 2310-3094
PERSPECTIVES OF DIRECT RENIN INHIBITOR - ALISKIREN
239 KB
This work is devoted to analysis strengths, weaknesses and prospects of using one of the new classes of antihypertensive drugs - direct renin inhibitors, in particular, a drug called aliskiren. To date, experimental and preclinical studies have shown that the drug has an antihypertensive, cardioprotective, nephroprotective, and vasoprotective effects. Aliskiren is indicated in patients with renovascular hypertension, chronic renal failure in patients with arterial hypertension, in hypertensive postmenopausal womenwith hyperactivation of the sympathetic nervous system and the metabolic syndrome, reducing the risk of severe cardiovascular disease due to such a variety provided effects. Interestingly, aliskiren not reduce blood pressure in healthy persons. Side effects include skin rashes, indigestion,angioedema. Aliskiren is contraindicated in severe chronic renal failure, 1 and 2type diabetes mellitus in combination with other groups of drugs influencing renin-angiotensin-aldosterone system, pregnancy, angioedema in history. Analyzing the properties of the drug can be concluded that it may be especially effective in the prevention of renal disease and to improve the prognosis for patients, and also exhibits a prolonged therapeutic effect in comparison with other antihypertensive agents.
aliskiren
renin
hypertension
chronic renal failure